Loading...

Bellus Health ($BLU)

Stock Image

BLU Overview

BELLUS Health, a clinical stage biopharmaceutical company, develops therapeutics for the treatment of chronic cough and other hypersensitization disorders.Its lead drug candidate includes BLU-5937, an oral small molecule antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of chronic cough and chronic pruritus.BELLUS Health Inc. was founded in 1993 and is headquartered in Laval, Canada. (From: StockAnalysis.com)

MORE ABOUT Bellus Health

Stay up to date with the best of Bullish each week.

BULLISH WEEKLY

Stay up to date with the best of Bullish each week.

CONVERSATIONS ABOUT Bellus Health